Application of all-trans retinoic acid combining chemotherapy and As4S4 in the maintenance treatment of patients with acute promyelocytic leukemia.
- Author:
Quan-de LIN
1
;
Xu-dong WEI
;
Ping WANG
;
Yan-yan LIU
;
Li-na ZHANG
;
Yu-fu LI
;
Quan-li GAO
;
Xing-hu ZHU
;
Yang-li ZHANG
;
Bai-jun FANG
;
Han YUE
;
Jian-wei DU
;
Dong-xia JIANG
;
Jie-ying HU
;
Yong-ping SONG
Author Information
- Publication Type:Journal Article
- MeSH: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; administration & dosage; adverse effects; Arsenicals; therapeutic use; Female; Humans; Leukemia, Promyelocytic, Acute; drug therapy; Male; Middle Aged; Remission Induction; Sulfides; therapeutic use; Treatment Outcome; Tretinoin; therapeutic use
- From: Chinese Journal of Hematology 2007;28(1):19-21
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo compare the efficacy of all-trans retinoic acid (ATRA) combining chemotherapy and As4S4 with ATRA combining chemotherapy for the maintenance treatment of patients with acute promyelocytic leukemia (APL).
METHODSSixty patients with APL induced to complete remission by ATRA and consolidated by chemotherapy were randomly divided into two groups. Thirty patients as As4S4 group received ATRA + As4S4 + chemotherapy, and another thirty patients as non-As4S4 group were treated only with ATRA + chemotherapy as maintenance therapy. The therapeutic effects, side effects and PML-RARalpha gene expression were analyzed.
RESULTSThe three-year continuous complete remission (CCR) rate was 90.0% for As4S4 group and 61.1% for non-As4S4 group, the difference being statistically significant. Significant difference was also found in the positive rate of PML-RARalpha fusion gene between the two groups. The side effects were mild.
CONCLUSIONAPL patients in maintenance therapy with ATRA + 6-MP + MTX + As4S4 can obtain a higher CCR.
